膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变合并HPV高危型感染的临床疗效

目的：研究膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变（CPL）合并HPV高危型（HR-HPV）感染的临床疗效。方法选择CPL合并HR-HPV感染患者108例，依照随机数字表法分为联合组（n=54）与对照组（n=54），对照组以重组人干扰素α-2b栓治疗，联合组在对照组基础上联合膦甲酸钠氯化钠注射液治疗，观察两组患者治疗前后HR-HPV病毒载量、子宫颈上皮瘤样病变（CIN）分级、T淋巴细胞水平、生活质量变化情况及不良反应。结果治疗后联合组HR-HPV病毒载量及生活质量评分显著低于对照组（P﹤0.05）。治疗后两组CIN各分级比例比较，差异有统计学意义（P﹤0.05）。治疗后联合组CD3+、CD4+、CD4+/CD8+水平高于对照组， CD8+水平低于对照组（P﹤0.05）。联合组总有效率（96.30%）高于对照组（79.63%）（P﹤0.05）。联合组不良反应发生率（7.41%）与对照组（5.56%）比较，差异无统计学意义（P﹥0.05）。结论膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗CPL合并HR-HPV感染可显著降低HR-HPV病毒载量，改善CIN分级及生活质量，临床疗效显著，不良反应发生率低，值得应用于临床。

Foscarnet sodium and sodium chloride combined with recombinant human interferon-α-2b suppository in the treatment of cervical precancerous lesions and high-risk HPV infection

Objectives To study the clinical efficacy of foscarnet sodium and sodium chloride combined with recom-binant human interferon-α-2b (rhIFNα-2b) suppository in the treatment of cervical precancerous lesions (CPL) and high-risk HPV (HR-HPV) infection. Method 108 cases of CPL combined with HR-HPV were included in the analysis, and were randomized as combined therapy group (n=54) and control group (n=54) as per a random number table, and there was no statistically significant differences in the baseline data for the two groups (P>0.05). rhIFNα-2b suppository was administered for control group, while the combined group was additionally given the forscarnet sodium injection, the HR-HPV viral load, CIN grade, T cells level changes and quality of life as well as adverse reactions of the two group were ob-served. Result After treatment, the HR-HPV viral load and the QoL score in combined therapy group were significantly lower than those in the control group (P<0.05);and the distribution of CIN grade was significantly different between the two groups (P<0.05);besides, the CD3+, CD4+, CD4+/CD8+levels were higher, while the CD8+level is lower in the com-bined therapy group compared with control group after treatment (P<0.05). The combined therapy group had higher over-all response rate (96.3%) than the control group (79.63%) (P<0.05), and the incidence of adverse reactions were similar in combined therapy group (7.41%) and control group (5.56%) (P>0.05). Conclusion Foscarnet sodium and sodium chlo-ride combined with rhIFNα-2b suppository may significantly reduce the HR-HPV viral load in the treatment of CPL com-bined with HR-HPV, improving the CIN grade and quality of life, with acceptable efficacy and low incidence of adverse reactions, which is clinically applicable.